Monday April 10, 2017
Today's Research Daily features new research reports on 17 major stocks, including Amazon (AMZN), Celgene (CELG), Facebook (FB) and Walgreens Boots (WBA).
Amazon shares have outperformed the broader market in the year-to-date period (the stock is up +19.3% vs. the +5.1% gain for the S&P 500 as a whole). The company delivered mixed fourth quarter results with only earnings exceeding expectations. A persistent concern in the Amazon story is the company's ever-growing need to build fulfillment centers that continues to weigh on its margins.
However, the analyst likes the company’s solid loyalty system in Prime and its FBA strategy, and content addition continues to add selection to Prime memberships. Also, the AWS generates much higher margins than retail, so it has a very positive impact on Amazon’s profitability. Amazon has agreed to pay $50 million to stream 10 NFL games during the upcoming 2017 season. (You can read the full research report on Amazon here.)
Shares of Celgene have gained +8.5% year to date, underperforming the Zacks Medical - Biomedical and Genetics sector which has gained +2.8% over the same period. Celgene and other drug makers’ shares have remained under pressure given ongoing questions about pricing issues and other regulatory uncertainties.
These issues notwithstanding, Celgene’s multiple myeloma drug Revlimid continues to grow on the back of market share gains and increased duration. The Zacks analyst likes Celgene’s ongoing label expansion efforts and pipeline development. The company anticipates several pipeline-related events over the upcoming quarters and next few years. Estimates remain static ahead of first-quarter results. (You can read the full research report on Celgene here.)
Facebook shares lagged the S&P 500 index following the election, but have more than made up for that underperformance since the start of 2017 - the stock is up +22.3% in the year-to-date period vs. +5.1% gain for the index in that time period. Despite strong results, Facebook, as expected, maintained a cautious stance on future growth prospects. Perhaps far more important to the market is the long-term opportunity for Facebook through monetization of key properties like Instagram, Messenger, WhatsApp and Oculus.
The prospect of higher engagement levels of its huge user base is another key positive in the Facebook story. The company is also dabbling in AR/VR and AI technologies, which also bode well for growth. Estimates have gone up ahead of the upcoming earnings release. (You can read the full research report on Facebook here.)
Shares of Walgreens Boots have done better than the embattled Zacks Retail-Drug Stores industry in the year-to-date period (WBA is down -0.5% vs. decline of -3.6% for the peer group), but the stock has lagged the broader Zacks Retail sector in that same time period. The stock has been helped somewhat by the expected integration synergy related to the impending Rite Aid deal.
Walgreens Boots reported a dull second-quarter fiscal 2017 with earnings meeting and expectations while sales fell behind. The company appears on track to execute strategic tie-ups and a cost reduction plan that is expected to strengthen margins. A strong balance sheet and a track record of returning excess cash to shareholders (pays an attractive dividend, currently yielding 1.8%) are some of the other positives in the Walgreens story. (You can read the full research report on Walgreens Boots here.)
Other noteworthy reports we are featuring today include DuPont (DD), Qualcomm (QCOM) and 21st Century Fox (FOXA).
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
See today's Zacks "Strong Sells" absolutely free >>.
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here >>>
Today's Must Read
Amazon (AMZN) Enters the Live Sports Streaming Business
Revlimid and Other Key Drugs to Drive Celgene's (CELG) Growth
Facebook (FB) Has Ample Growth Catalysts but Risks Remain
Walgreens Boots (WBA) Q2 Sales Fall Y/Y
Monsanto (MON) Beats on Q2 Earnings and Revenues
High demand, innovation projects and Bayer's buyout deal will drive near-term results, per the covering analyst.
Kroger's (KR) Strategic Efforts Bode Well, Risks Remain
The Zacks analyst thinks Kroger's operational strategies to augment identical supermarket sales and operating margin bode well in a competitive and a deflationary environment.
Yum! Brands (YUM) Looks to Grow Post China Unit Spin Off
The covering analyst thinks Yum! Brands' focus on development of its three iconic global brands, increasing franchise ownership and efficiency should aid in subsidizing the effects of the spin off.
Syncrude Stake Boosts Suncor (SU), Pricing Woes Remain
The Zacks analyst thinks Suncor's prospects have improved after the company increased its stake in the Syncrude oilsands project.
DuPont (DD) Poised on Cost Actions Amid FX, Market Headwinds
While DuPont faces currency headwind and challenges from weak agricultural market conditions, its aggressive cost actions should continue to lend support to its earnings, per the covering analyst.
Alaska Air Group (ALK) to End Virgin America Brand in 2019
The Zacks analyst is impressed by the company's efforts to expand. Despite integration risks, the Virgin America acquisition is a big positive.
21st Century Fox (FOXA) Rides on Cable Network Programming
The covering analyst thinks 21st Century Fox's Cable Network Programming has been driving its performance owing to rising affiliate fees.
Principal Financial's (PFG) Inorganic Growth Impresses
The Zacks analyst believes that Principal Financial's inorganic growth will remain impressive with prudent acquisitions. Such deals should also strengthen and expand the company's global footprint.
Caterpillar (CAT) To Benefit from Infrastructure Spend Plan
The covering analyst believes Caterpillar will gain immensely from Trump's infrastructure-spending program that will help it recover footing in the construction and mining markets.
Ameriprise's (AMP) Strong Revenue Growth to Aid Profitability
The Zacks analyst thinks Ameriprise is well poised for growth as its efforts in launching new products to keep pace with dynamic market needs will support top-line growth in the upcoming quarters.
Qualcomm (QCOM) Downgraded to Sell Amidst Stiff Competition
The Zacks analyst thinks competitive mobile phone chipset market may hurt Qualcomm's profits in future. Lawsuits and fines on anti-competitive practices are other risks.
Cigna (CI) Hurt by CMS Restriction, Tussle With Anthem
Cigna's conflict with Anthem continues which raises doubts on the receipt of termination fee of $1.85 billion. Restriction by the CMS on sale of Medicare Advantage plans, will hurt membership in 2017
Soft Defib Sales, Currency Woes Worry (BSX)
The Zacks analyst thinks despite Symetis buyout related optimism, Boston Scientific's shares are underperforming the broader industry on continued sluggish defibrillator sales and currency woes.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report
QUALCOMM Incorporated (QCOM): Free Stock Analysis Report
Twenty-First Century Fox, Inc. (FOXA): Free Stock Analysis Report
Facebook, Inc. (FB): Free Stock Analysis Report
E.I. du Pont de Nemours and Company (DD): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
Amazon.com, Inc. (AMZN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research